The premier interdisciplinary rehabilitation solution since 2003! Brainworks focuses in client-centred rehabilitation services for individuals who have been seriously injured in motor vehicle collisions, and their families. Brainworks offers innovative treatment programs to individuals with brain injury, chronic pain, depression & sleep disturbances. We provide direct rehabilitation services north of Toronto to north of Sudbury, with consultation, education & eRehabilitation service capabilities throughout Ontario.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

ANTHEIA AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO ACCELERATE PRODUCTION OF ESSENTIAL MEDICINES USING SYNTHETIC BIOLOGY

Antheia | August 13, 2021

news image

Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the development and production of essential medicines. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ: SRNG), serves customers across industries seeking to develop new and better products. Antheia plans to leverage Ginkgo...

Read More

WITH AN EYE ON THE CLINIC, ATLAS-BACKED KYMERA SECURES $102 MILLION

BioSpace | March 12, 2020

news image

Cambridge, Mass.-based Kymera Therapeutics closed a $102 million Series C funding round to continue advancing the company’s lead targeted protein degradation asset for oncology and immunology. Kymera's lead program targets IRAK4, a protein that is known to play a significant role in inflammation that is mediated by toll-like and IL-1 receptors. Kymera aims to advance its IRAK4 degrader program in a variety of autoinflammatory and autoimmune diseases, as well as in precision-medicine ta...

Read More

CELL AND GENE THERAPY

ANUVA ANNOUNCES SERIES A CLOSURE AND ENTERS INTO A STRATEGIC PARTNERSHIP WITH HELIX

Anuva and Helix | August 30, 2022

news image

Anuva enters into its next stage of growth focused on creating the most diverse Genomic Bio / Data Bank at scale. To enable this, Anuva is entering into a global strategic partnership with Helix, the leading population genomics and viral surveillance company in the United States. Anuva will be generating new knowledge on health and disease, directly applicable to treatments, on diverse under-represented populations to advance drug discovery through the identification of novel targ...

Read More

AKREVIA REBRANDS AS XILIO THERAPEUTICS, SNAGS $100 MILLION IN SERIES B

BioSpace | March 02, 2020

news image

Two years after Cambridge, Mass.-based Akrevia Therapeutics launched, the company has rebranded itself as Xilio Therapeutics and secured $100.5 million in a Series B financing round that will be used to advance its lead therapeutic candidates into clinical studies. The financing will be used to progress Xilio’s first two therapeutic candidates, XTX201 (tumor-selective IL-2) and XTX101 (tumor-selective aCTLA4 mAb) through Investigational New Drug (IND) enabling studies and into Phase I clin...

Read More
news image

INDUSTRIAL IMPACT

ANTHEIA AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO ACCELERATE PRODUCTION OF ESSENTIAL MEDICINES USING SYNTHETIC BIOLOGY

Antheia | August 13, 2021

Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the development and production of essential medicines. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ: SRNG), serves customers across industries seeking to develop new and better products. Antheia plans to leverage Ginkgo...

Read More
news image

WITH AN EYE ON THE CLINIC, ATLAS-BACKED KYMERA SECURES $102 MILLION

BioSpace | March 12, 2020

Cambridge, Mass.-based Kymera Therapeutics closed a $102 million Series C funding round to continue advancing the company’s lead targeted protein degradation asset for oncology and immunology. Kymera's lead program targets IRAK4, a protein that is known to play a significant role in inflammation that is mediated by toll-like and IL-1 receptors. Kymera aims to advance its IRAK4 degrader program in a variety of autoinflammatory and autoimmune diseases, as well as in precision-medicine ta...

Read More
news image

CELL AND GENE THERAPY

ANUVA ANNOUNCES SERIES A CLOSURE AND ENTERS INTO A STRATEGIC PARTNERSHIP WITH HELIX

Anuva and Helix | August 30, 2022

Anuva enters into its next stage of growth focused on creating the most diverse Genomic Bio / Data Bank at scale. To enable this, Anuva is entering into a global strategic partnership with Helix, the leading population genomics and viral surveillance company in the United States. Anuva will be generating new knowledge on health and disease, directly applicable to treatments, on diverse under-represented populations to advance drug discovery through the identification of novel targ...

Read More
news image

AKREVIA REBRANDS AS XILIO THERAPEUTICS, SNAGS $100 MILLION IN SERIES B

BioSpace | March 02, 2020

Two years after Cambridge, Mass.-based Akrevia Therapeutics launched, the company has rebranded itself as Xilio Therapeutics and secured $100.5 million in a Series B financing round that will be used to advance its lead therapeutic candidates into clinical studies. The financing will be used to progress Xilio’s first two therapeutic candidates, XTX201 (tumor-selective IL-2) and XTX101 (tumor-selective aCTLA4 mAb) through Investigational New Drug (IND) enabling studies and into Phase I clin...

Read More